Summary: Prostate tumors can develop resistance to androgen receptor (AR)–targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).

中文翻译：

---

为什么 ARNT 前列腺肿瘤对恩杂鲁胺有反应？

摘要：前列腺肿瘤可以通过治疗诱导的转录因子活性变化（促进神经内分泌谱系的转录和形态学特征）产生对雄激素受体（AR）靶向治疗的耐药性。这项研究发现了昼夜节律蛋白 ARNTL 在第二代 AR 靶向疗法 enzalutamide 耐药性中的意外作用。请参阅 Linder 等人的相关文章，第 17 页。2074（4）。